|Bid||8.14 x 800|
|Ask||8.24 x 800|
|Day's range||8.00 - 8.23|
|52-week range||6.99 - 52.11|
|Beta (5Y monthly)||3.01|
|PE ratio (TTM)||N/A|
|Earnings date||16 Nov 2022 - 21 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||25.16|
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.
As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...
CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.